You are here
Victoza Beats Metformin in Diabetes Study
The results may help the Danish drugmaker, which funded the study published in the Lancet journal, to differentiate its medicine in a highly competitive marketplace.
Victoza is Novo's biggest new drug hope and is expected to generate annual sales of more than $1.4 billion by 2014, according to consensus forecasts compiled by Thomson Reuters.
To read the abstract in the Lancet study, click here.
To read the Reuters story, read it here.